Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of everolimus with thoracic radiotherapy in non-small cell lung cancer
NL-OMON33139Phase 1Withdrawn
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of everolimus in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Tolerability. Planned start Oct 2009; status: withdrawn.
02
Drugs
everolimus
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON33139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33139.